The twice-yearly HIV prevention shot has gone from breakthrough to rollout. Now the question is how fast it can reach the people who want it. On October 21, 2026, the HIV prevention advocacy groups AVAC and Access Bridge called on governments, donors and drugmakers to reach at least 3 million people with injectable lenacapavir (LEN) for PrEP by the end of 2027. Three days later, an Associated Press report from Uganda showed the other side of the story: clinics where people ask for the shot and are told it has run out.

The short version: Lenacapavir, sold in the US as Yeztugo, is a PrEP injection given once every six months. In clinical trials it was highly effective at preventing HIV. Supply, price and funding are now deciding who can actually get it. For HIV-negative people, including partners in mixed-status relationships, it's one more prevention option worth knowing about.

What is lenacapavir PrEP?

PrEP (pre-exposure prophylaxis) is medicine that HIV-negative people take to lower their chance of getting HIV. Until recently the choices were a daily pill or a cabotegravir shot every two months. Lenacapavir is a long-acting HIV medicine given as an injection under the skin once every six months, after a starting dose of shots plus tablets.

The US Food and Drug Administration approved it for PrEP on June 18, 2025. In September 2025, the CDC published a strong recommendation for lenacapavir as a PrEP option for adults and adolescents weighing at least 77 lbs (35 kg) who would benefit from PrEP. According to the CDC's review of the two large trials, PURPOSE 1 and PURPOSE 2:

• Among young cisgender women, there were no new HIV infections in the lenacapavir group over 52 weeks, which the CDC reports as 100% efficacy compared with background HIV rates.
• In a mostly male trial population, efficacy was 96% compared with background rates.
• The most common side effects were mild to moderate injection site reactions. A small lump (nodule) under the skin where the shot was given was common and could last for months.

The new push: 3 million people by the end of 2027

According to AVAC's October 21, 2026 announcement, as of October 2026 lenacapavir for PrEP:

• is recommended by the World Health Organization,
• has 19 regulatory approvals,
• is part of 36 implementation science projects, and
• is being introduced in public health programs in 29 countries with support from the Global Fund and PEPFAR.

AVAC says doses for 600,000 people were ordered for 2026. To reach 3 million people by the end of 2027, and 20 million by 2030, the groups are asking the Global Fund and PEPFAR to order now for at least 2.4 million people in 2027. They also want regulators to approve lower-priced generic versions quickly, and drugmakers to guarantee supply. "Scientific breakthroughs only matter if they reach the people who need them," said AVAC Executive Director Mitchell Warren.

The reality on the ground: not enough doses yet

The AP report published October 24, 2026 describes the gap in Mbarara, a city in western Uganda where the HIV rate is about 10%, double the national average. The few thousand lenacapavir doses Uganda has received are being rationed across the country. People who ask for it are often offered the every-two-month cabotegravir shot instead. One woman told AP that when she goes to check, "they tell me that it is finished." Local workers also said funding cuts have ended many community outreach visits that used to bring testing and PrEP closer to people.

The bigger numbers, which AP attributed to the Global Fund, show both progress and the size of the gap:

• The 2026 target is to reach 600,000 people in 24 countries.
• By mid-September 2026, 430,000 doses had been delivered (327,000 starting doses and 103,000 continuation doses).
• National programs reported more than 118,000 people receiving lenacapavir.

In a statement to AP, Gilead, the drug's maker, said it is providing lenacapavir at no profit through the Global Fund and PEPFAR while licensed generic manufacturers scale up, with initial generic supply expected in late 2026 and widespread generic availability expected in 2027.

Why price matters

UNAIDS noted in an October 20, 2026 feature that when lenacapavir was approved in the US, Gilead set a list price of $28,218 per person per year. UNAIDS welcomed deals with generic producers in September 2025 that would bring the price for HIV prevention down to $40 per person per year. South Africa began rolling out lenacapavir on June 5, 2026, starting with about 360 public clinics and health facilities in six provinces.

What this means for dating and relationships

For our community, the headline isn't only about global health. It's about having more ways to protect each other and feel at ease.

• U=U still comes first in mixed-status couples. A partner with HIV who takes treatment and stays undetectable does not pass HIV through sex. Read more in our guide to what U=U means for dating and relationships, and see the latest real-world results on long-acting HIV treatment shots.
• PrEP adds a layer for the HIV-negative partner. The CDC lists people whose partners have HIV that isn't yet suppressed among those who may benefit from PrEP. Some couples also use PrEP while a partner is newly starting treatment, or simply for peace of mind. Our guide on serodiscordant couples covers how partners make these choices together.
• Twice a year can mean less daily stress. A shot every six months means no daily pill to remember or hide, which matters to many people.
• PrEP doesn't prevent other STIs. The US prescribing information advises using lenacapavir alongside safer sex practices, including condoms, to reduce the risk of other sexually transmitted infections. See how condoms, antivirals and PrEP layer together, and keep up with regular STI testing.

If you're thinking about the shot

Lenacapavir PrEP is only for people who are HIV-negative. Questions to raise with a health care provider:

• Testing. You need a negative HIV test before you start and before each injection. Taking lenacapavir with undiagnosed HIV can lead to drug resistance.
• Timing. Shots are due every six months (26 weeks, give or take two weeks). Ask what to do if you know you'll be late.
• Stopping. According to the CDC, the drug stays in your body long after your last shot but doesn't protect you after six months. If you stop and still want protection, switch to another PrEP option on time.
• Cost and coverage. In the US, ask your provider or pharmacist how your plan covers it, and whether a pill or the every-two-month shot fits you better.

The bottom line

The twice-yearly PrEP shot is one of the biggest advances in HIV prevention in years, and it's now in national programs in dozens of countries. Getting it to everyone who wants it depends on supply, price and funding decisions being made right now. Wherever you live, more prevention options mean more ways for people with different HIV statuses to date, love and plan a future together. If you're ready to meet people who already understand, explore HIV dating on MeetPositives.

Sources

• AVAC, "AVAC, Access Bridge Call for Accelerated Ambition to Reach at Least Three Million People with Lenacapavir for HIV Prevention by the End of 2027," October 21, 2026.
• Associated Press via Africanews, "HIV prevention jab offers hope in Uganda but doses are hard to find," October 24, 2026.
• CDC, "Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025," MMWR, September 18, 2025.
• UNAIDS, "I was in a cage. LEN gave me freedom," October 20, 2026.
• Yeztugo (lenacapavir) US Prescribing Information summary, Gilead Sciences.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney.